Molbio Diagnostics IPO Opens on August 10: Price Band, GMP, Financials, Key Dates and Should You Apply?

Molbio Diagnostics IPO is set to open for subscription on August 10, 2026, offering investors an opportunity to participate in one of India's leading molecular diagnostics companies. The ₹939.70 crore Mainboard IPO comprises a fresh issue of ₹200 crore along with an Offer for Sale (OFS) worth ₹739.70 crore. The company plans to utilize the fresh proceeds for expanding its research and development infrastructure, purchasing manufacturing equipment, and meeting general corporate requirements.

The IPO comes at a time when the healthcare diagnostics industry continues to witness rising demand for rapid disease detection, molecular testing, and advanced diagnostic technologies. Backed by its proprietary Truenat molecular diagnostics platform, global presence across more than 90 countries, and strong financial growth, Molbio Diagnostics has attracted considerable attention from both institutional and retail investors. Adding to the positive sentiment, the grey market premium (GMP) has remained strong ahead of the issue opening, indicating expectations of healthy listing gains.

Molbio Diagnostics IPO Details

Particulars	Details
IPO Type	Book Built Issue
IPO Size	₹939.70 Crore
Fresh Issue	₹200 Crore
Offer For Sale	₹739.70 Crore
IPO Opens	August 10, 2026
IPO Closes	August 12, 2026
Allotment	August 13, 2026
Listing Date	August 17, 2026
Price Band	₹768 – ₹807 per share
Face Value	₹1
Lot Size	18 Shares
Minimum Investment	₹14,526
Listing Exchange	BSE & NSE

Molbio Diagnostics IPO GMP Today

The Molbio Diagnostics IPO GMP remains positive ahead of the subscription opening. As of August 7, the latest Grey Market Premium stands at ₹180, indicating an estimated listing price of around ₹987 per share, based on the upper price band of ₹807. While GMP has moderated slightly from the previous day, it continues to reflect strong investor interest.

Molbio Diagnostics IPO GMP Trend

GMP Date	IPO Price	GMP	Estimated Listing Price	Estimated Profit per Lot
10 Aug 2026	₹807	₹138 ▲	₹945 (17.10%)	₹2,484
09 Aug 2026	₹807	₹132 ▲	₹939 (16.36%)	₹2,376
08 Aug 2026	₹807	₹130 🔻	₹937 (16.11%)	₹2,340
07 Aug 2026	₹807	₹180 🔻	₹987 (22.30%)	₹3,240
06 Aug 2026	₹807	₹220 ▲	₹1,027 (27.26%)	₹3,960
05 Aug 2026	₹807	₹170 ▲	₹977 (21.07%)	₹3,060
04 Aug 2026	₹807	₹0 ➖	₹807 (0.00%)	₹0

Disclaimer: GMP is sourced from the grey market and is only an unofficial indicator. It does not guarantee listing gains. Investors should conduct their own research before investing.

About the Company

Founded in 2000, Molbio Diagnostics is a healthcare technology company focused on point of care molecular diagnostics. The company develops, manufactures and commercializes rapid testing solutions for infectious and non-communicable diseases using its proprietary Truenat platform, a portable PCR-based molecular testing system capable of delivering results in less than an hour.

The company currently offers diagnostic solutions for more than 30 diseases through 43 molecular diagnostic assays, including tuberculosis (TB), COVID-19, HIV, Hepatitis B, Hepatitis C and HPV. Apart from molecular diagnostics, the company has also expanded into digital pathology, radiology and breast health screening through strategic collaborations and acquisitions.

Molbio operates six manufacturing facilities across India, serves customers in over 90 countries, and supplies products to governments, hospitals, laboratories and international healthcare organizations. The company employs more than 1,225 professionals across research, manufacturing, quality assurance, sales and corporate functions.

Molbio Diagnostics Financial Performance

The company has delivered healthy financial growth over the last financial year.

Financials (₹ Crore)	FY26	FY25	Growth
Total Income	1,455.17	1,027.94	42%
Profit After Tax	164.14	138.58	18%
EBITDA	328.24	256.64	28%
Net Worth	1,144.68	952.95	-
Total Assets	2,148.42	1,461.56	-

The combination of strong revenue growth, improving profitability and expanding global operations has strengthened the company's position within the healthcare diagnostics industry.

Objects of the IPO

The company plans to utilize the fresh issue proceeds for the following purposes:

Purpose	Amount
Research & Development Centre and Centre of Excellence	₹125.12 Crore
Purchase of Plant & Machinery	₹80.81 Crore
General Corporate Purposes	Remaining Amount

Molbio Diagnostics IPO Reservation

Category	Reservation
Qualified Institutional Buyers (QIB)	Not more than 50%
Retail Investors	Not less than 35%
Non-Institutional Investors (NII)	Not less than 15%

Molbio Diagnostics IPO Lot Size

Application	Lots	Shares	Investment
Retail Minimum	1	18	₹14,526
Retail Maximum	13	234	₹1,88,838
Small HNI	14	252	₹2,03,364
Big HNI	69	1,242	₹10,02,294

Key Strengths

• Proprietary Truenat molecular diagnostics platform with WHO-endorsed TB testing technology.
• Presence across 90+ countries with strong institutional and government customers.
• Recurring revenue model supported by diagnostic consumables and testing kits.
• Strong in-house research & development capabilities backed by global patents.
• Diversified healthcare diagnostics portfolio beyond infectious disease testing.
• Expanding manufacturing capacity and international footprint.

Should You Apply for the Molbio Diagnostics IPO?

Molbio Diagnostics enters the public markets with strong industry positioning, healthy financial growth and a scalable diagnostics business model. The company reported 42% revenue growth and 18% growth in profit after tax during FY26 while continuing to invest in research, manufacturing and global expansion.

The PO is currently attracting positive market sentiment, supported by a healthy Grey Market Premium (GMP). However, investors should also note that the issue is valued at a post-issue P/E of around 56.7x, making valuation an important consideration. Long-term investors may evaluate the company's innovation pipeline, recurring revenue model and growth opportunities in global molecular diagnostics before making an investment decision.

What is the Molbio Diagnostics IPO date?

The Molbio Diagnostics IPO will open for subscription on August 10, 2026, and close on August 12, 2026. The shares are expected to be listed on the BSE and NSE on August 17, 2026.

What is the price band and lot size of the Molbio Diagnostics IPO?

The Molbio Diagnostics IPO price band has been fixed at ₹768 to ₹807 per share. Investors can apply with a minimum lot size of 18 shares, requiring a minimum investment of ₹14,526 at the upper price band.

What is the latest GMP of the Molbio Diagnostics IPO?

As of August 7, 2026, the Molbio Diagnostics IPO GMP stands at ₹180, indicating an estimated listing price of around ₹987 per share. However, GMP is unofficial and should not be considered a guarantee of listing gains.

What does Molbio Diagnostics do?

Molbio Diagnostics is a healthcare diagnostics company specializing in point-of-care molecular diagnostic solutions. Its proprietary Truenat platform enables rapid PCR-based testing for diseases such as tuberculosis (TB), COVID-19, HIV, Hepatitis B & C, HPV, and several other infectious and non-communicable diseases.

Should investors apply for the Molbio Diagnostics IPO?

The Molbio Diagnostics IPO offers exposure to a rapidly growing molecular diagnostics company with strong revenue growth, expanding global operations, and a scalable healthcare technology platform. While the IPO has generated positive grey market interest, investors should also evaluate its valuation, financial performance, business fundamentals, and long-term growth prospects before making an investment decision.